Multidrug therapy increases the risk for drug-drug interactions. Clopidogrel, a prodrug, requires hepatic cytochrome P450 (CYP) metabolic activation to produce the active metabolite that inhibits the platelet P2Y 12 adenosine diphosphate (ADP) receptor, decreasing platelet activation and aggregation processes. Atorvastatin, omeprazole, and several other drugs have been shown in pharmacodynamic studies to competitively inhibit CYP activation of clopidogrel, reducing clopidogrel responsiveness. Conversely, other agents increase clopidogrel responsiveness by inducing CYP activity. The clinical implications of these pharmacodynamic interactions have raised concern because many of these drugs are coadministered to patients with coronary artery disease. There are multiple challenges in proving that a pharmacodynamic drug-drug interaction is clinically significant. To date, there is no consistent evidence that clopidogrel-drug interactions impact adverse cardiovascular events. Statins and proton pump inhibitors have been shown to decrease adverse clinical event rates and should not be withheld from patients with appropriate indications for therapy because of concern about potential clopidogrel-drug interactions. Clinicians concerned about clopidogreldrug interactions have the option of prescribing either an alternative platelet P2Y 12 receptor inhibitor without known drug interactions, or statin and gastro-protective agents that do not interfere with clopidogrel metabolism. Dual antiplatelet therapy with aspirin and clopidogrel is recommended treatment for percutaneous coronary intervention (PCI) (1) and acute coronary syndromes (ACS) (2,3). Whereas multidrug therapy with antiplatelet drugs, lipid-lowering and glucose-lowering agents, antihypertensive drugs, and even antidepressants has been suggested as a therapeutic strategy to reduce cardiovascular risk, multiple drug prescriptions increase the risk for drug-drug interactions. This is particularly true if more than 1 agent requires significant hepatic metabolism (4). Clopidogrel, atorvastatin, omeprazole, and many other drugs require hepatic cytochrome P450 (CYP) metabolism. Importantly, clopidogrel-atorvastatin (5) and clopidogrel-omeprazole (6) drug interactions have been described that limit the ability of clopidogrel to inhibit platelet activation and aggregation processes. The clinical implications of these pharmacodynamic interactions have raised concern because many of these drugs are concomitantly administered to patients with coronary artery disease (7, 8) . The purpose of this review is to summarize the pharmacodynamic and clinical evidence regarding these drug interactions and other clopidogrel-drug interactions.
Dual antiplatelet therapy with aspirin and clopidogrel is recommended treatment for percutaneous coronary intervention (PCI) (1) and acute coronary syndromes (ACS) (2, 3) . Whereas multidrug therapy with antiplatelet drugs, lipid-lowering and glucose-lowering agents, antihypertensive drugs, and even antidepressants has been suggested as a therapeutic strategy to reduce cardiovascular risk, multiple drug prescriptions increase the risk for drug-drug interactions. This is particularly true if more than 1 agent requires significant hepatic metabolism (4) . Clopidogrel, atorvastatin, omeprazole, and many other drugs require hepatic cytochrome P450 (CYP) metabolism. Importantly, clopidogrel-atorvastatin (5) and clopidogrel-omeprazole (6) drug interactions have been described that limit the ability of clopidogrel to inhibit platelet activation and aggregation processes. The clinical implications of these pharmacodynamic interactions have raised concern because many of these drugs are concomitantly administered to patients with coronary artery disease (7, 8) . The purpose of this review is to summarize the pharmacodynamic and clinical evidence regarding these drug interactions and other clopidogrel-drug interactions.
Drug Metabolism
The most important metabolic pathway for most medications involves oxidation by 1 or more CYP isoenzymes. These isoenzymes are generally most highly expressed in hepatocytes, but are also present in other tissues including the intestines and skin. As oxidative metabolism is the first step in the clearance of many drugs, CYP isoenzymes are central to many clinically relevant drug-drug interactions. The activity of CYP isoenzymes may also be a necessary step for conversion of a prodrug to a clinically beneficial active metabolite.
Clopidogrel bisulfate, an inactive thienopyridine prodrug, is 85% hydrolyzed in vivo by esterases to an inactive carboxylic acid derivative (Fig. 1) . The remaining drug undergoes oxidative biotransformation to its active thiol metabolite by a 2-step, CYP-dependent process in which CYP3A4/5 and CYP2C19 have the greatest roles, with lesser involvement from CYP2B6, CYP1A2, and CYP2C9 (9) . The active metabolite then irreversibly inhibits the platelet P2Y 12 adenosine diphosphate (ADP) receptor by forming an inactivating disulfide bond with cysteine on the P2Y 12 receptor (10) . This blocks ADP from binding to the receptor and stimulating platelet activation and aggregation. Physical and genetic factors that induce, inhibit, or compete for CYP activity can modulate biotransformation of clopi-dogrel to its active metabolite and result in interindividual variability of clopidogrel responsiveness. For instance, the degree of CYP3A4 metabolic activity is inversely related to the antiplatelet effects of clopidogrel (11) . CYP2C19 polymorphisms associated with enzymatic activity also impact clopidogrel metabolism and responsiveness (12) .
Statins act by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of cholesterol synthesis in the liver. CYP3A4 is important for the elimination of lipophilic statins (lovastatin, simvastatin, and atorvastatin), but hydrophilic statins (fluvastatin, pravastatin, and rosuvastatin) are not significantly metabolized by this isoenzyme. Atorvastatin is the most commonly prescribed statin, and its extensive hepatic metabolism has the potential to result in significant interactions with other drugs (13) . Atorvastatin calcium is initially converted to the acid and lactone metabolites of the parent drug. Whereas the acid form inhibits HMG-CoA reductase, the dominant pathway of elimination is through the lactone form that binds more tightly to CYP3A4 than many other substrates and competes with a large number of medications, including itraconazole, nelfinavir, ritonavir, cyclosporine, fibrates, erythromycin, amiodarone, verapamil, fluoxetine, and nefazadone, as well as grapefruit juice.
Proton pump inhibitors (PPIs) are prodrugs that are activated in gastric parietal cells. PPIs irreversibly inhibit the gastric H ϩ /K ϩ ATPase (the proton pump) that accomplishes the final step in acid secretion. Omeprazole, the most widely used PPI, is metabolized to hydroxyomeprazole and omeprazole sulphate primarily by CYP2C19 and CYP3A4 (14) . Omeprazole has a greater affinity for CYP2C19 than CYP3A4, compared with the other PPIs that are also metabolized by these isoenzymes, and therefore Figure 1 Clopidogrel-Drug Interactions
After ingestion and absorption, 85% of clopidogrel bisulfate is hydrolyzed by esterases to an inactive carboxylic acid metabolite and the remaining drug is oxidized in a 2-step process by hepatic P450 cytochromes. Multiple pharmacodynamic drug interactions can influence active thiol metabolite levels. cAMP ϭ cyclic adenosine monophosphate; PPI ϭ proton pump inhibitor.
has a greater potential for drug-drug interactions mediated by CYP2C19. Omeprazole has been shown to reduce the clearance of diazepam, phenytoin, and warfarin. Conversely, ketaconazole and clarithromycin have a high affinity for CYP3A4 and increase omeprazole concentrations. Another mechanism by which omeprazole may induce drug interactions is by elevating gastric pH and altering drug absorption rates. Due to their common requirement for CYP3A4 metabolism, a clopidogrel-atorvastatin interaction may exist. Similarly, due to their common requirement for CYP2C19 metabolism, a clopidogrel-omeprazole interaction may exist. These interactions could result in competitive inhibition decreasing the conversion of the clopidogrel prodrug to the active metabolite and could potentially translate into an increased risk for cardiovascular events because of inadequate platelet P2Y 12 receptor inhibition. This is a particularly important issue since many patients receiving treatment to prevent recurrent cardiovascular events are suitable candidates for all 3 drugs.
Pharmacodynamic Studies
The clopidogrel-atorvastatin interaction. We initially surmised that clopidogrel was metabolized in humans by CYP3A4, not CYP1A2 as described in the rat (15), when we serendipitously noted that patients on atorvastatin were not achieving the expected platelet inhibition with a clopidogrel 300-mg loading dose (5), an observation confirmed by Neubauer et al. (16) . Responding to criticism that our initial study was observational and used a point-of-care platelet aggregometer, we subsequently performed a prospective randomized trial with standard light transmission aggregometry and demonstrated an interaction with a 300-mg, but not a 600-mg, clopidogrel loading dose (17) . Consistent with these findings, results from an in vitro study using human microsomes containing single CYP isozymes indicated that both CYP3A4 and CYP3A5 were primarily responsible for oxidation of clopidogrel to its active metabolite. Exposure of human microsomes to clopidogrel and atorvastatin lactone at equimolar concentrations resulted in a Ͼ90% inhibition of clopidogrel metabolism (18) .
However, other studies (Table 1) have shown no impact with clopidogrel and atorvastatin coadministration (19 -22) , especially when a higher clopidogrel loading dose (600 mg) was tested (23) (24) (25) (26) , when measurements were made several weeks later (21, (27) (28) (29) , or when atorvastatin was added to clopidogrel (31) (32) . Limitations of the ex vivo platelet aggregation studies include small sample sizes, different drug doses, heterogeneous patient populations on multiple medications, and differences in measurement techniques and protocols. Moreover, it is unknown how the variability in clopidogrel metabolism due to CYP2C19 polymorphisms and CYP3A4 expression might have impacted the results. Expression of CYP3A4 varies 40-fold in humans, and metabolism of CYP3A4 substrates varies 10-fold in vivo (33) .
In summary, no one disputes our initial finding that clopidogrel is metabolized by CYP3A4, recognized by platelet aggregometry because of a presumed clopidogrelatorvastatin interaction, but many other reports have not been able to confirm this interaction for various reasons. The clopidogrel-omeprazole interaction. Gilard et al. (6) initially observed an association between PPI use and poor clopidogrel response (Table 2 ). They subsequently demonstrated that more patients on omeprazole than placebo were nonresponders after clopidogrel administration (34 (44) is enrolling 320 patients treated with dual antiplatelet therapy for at least 60 days after bare-metal stent implantation. Patients will receive either atorvastatin 80 mg or the comparator rosuvastatin 20 mg daily for 12 months. After 1 month, they will also receive either omeprazole 20 mg, pantoprazole 40 mg, esomeprazole 40 mg, or the histamine 2 -receptor antagonist (H 2 RA) comparator ranitidine 300 mg daily for 11 months. Percentage change in residual platelet aggregation by light transmittance aggregometry and percentage change in platelet reactivity index by flow cytometry will be measured AU ϭ aggregation unit; PPI ϭ proton pump inhibitor; PRI ϭ platelet reactivity index; RCT ϭ randomized clinical trial; VASP ϭ vasodilator-stimulated phosphoprotein; other abbreviations as in Table 1 .
at 30 and 60 days. Death, myocardial infarction (MI), ischemia-driven repeat revascularization, stroke, gastrointestinal bleeding, and peptic ulcer disease will be documented at 30 days, 60 days, and 1 year. Unfortunately, this protocol will not evaluate the interaction we described when a loading dose of clopidogrel is given to a patient on chronic atorvastatin therapy, nor will it measure the early potential interaction between omeprazole and clopidogrel.
Clinical Studies
The clopidogrel-atorvastatin interaction. (25, 26) . In other studies, there was an insignificant trend for worse outcomes with atorvastatin compared with pravastatin or no statin (45,46,52,53) and with CYP-metabolized statins compared with non-CYPmetabolized statins (51-53), but no consistent signal for increased cardiovascular risk with drug coadministration.
The clopidogrel-omeprazole interaction. REGISTRY REPORTS.
A letter to the editor first suggested that PPI exposure increased the rate of MI in patients on clopidogrel (55) . Two small (56,57) and 1 large (58) single-center reports supported increased adverse cardiac events in patients discharged on a PPI after PCI. Conversely, omeprazole and other PPIs had no effect on the clinical response to clopidogrel in the FAST-MI (French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction) registry that enrolled 2,208 patients with MI and assessed 1-year risk for death, MI, and stroke (59 . Both studies showed higher risk for patients on PPIs, suggesting that comorbidities, rather than a clopidogrel-PPI interaction, may make patients higher risk for adverse cardiac events.
RANDOMIZED CLINICAL TRIAL.
The COGENT (Clopidogrel and the Optimization of Gastrointestinal Events Trial) randomized 3,627 patients with ACS or PCI to a fixed-dose combination of controlled-release omeprazole 20 mg-clopidogrel 75 mg/day or clopidogrel alone, but was terminated early because of sponsor bankruptcy (71) . Although underpowered, the secondary combined cardiovascular end point of cardiovascular death, ischemic stroke, nonfatal MI, or revascularization was not different (HR: 1.02, 95% CI: 0.70 to 1.51), but the composite primary gastrointestinal event rate was reduced with PPI use (HR: 0.55, 95% CI: 0.36 to 0.85). Not quantitated Risk associated with PPI use, not coadministration CABG ϭ coronary artery bypass graft; HR ϭ hazard ratio; RR ϭ risk ratio; other abbreviations as in Tables 1, 2 , and 3.
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In summary, patients who receive PPIs are older and have more comorbidity, making confounding and selection bias a likely explanation for increased clinical risk in some observational studies. Whereas observational studies have produced discordant results for a clopidogrel-omeprazole interaction, post hoc randomized clinical trial reports (39, 70) and 1 randomized clinical trial (71) have shown no signal for increased cardiovascular risk with drug coadministration.
Other Clopidogrel-Drug Interactions
We initially demonstrated that CYP3A4 inhibitors (erythromycin, troleandomycin, ketoconazole) decreased and CYP3A4 inducers (rifampin) increased the antiplatelet activity of clopidogrel (5, 11) . Several other clopidogreldrug interactions have subsequently been described (Fig. 1) . CYP inhibitors. Ketoconazole is a potent inhibitor of both CYP3A4 and CYP3A5. Healthy subjects given loading and maintenance doses of clopidogrel had decreased production of active metabolite and significantly reduced platelet inhibition on ketoconazole compared with control (72) . Similarly, the CYP3A inhibitor itraconazole significantly decreased the ability of clopidogrel to inhibit platelet aggregation (73) .
Dihydropyridine calcium channel blockers (nifedipine, amlodipine) also inhibit CYP3A4. In observational studies, they have been shown to decrease clopidogrel responsiveness as measured by the vasodilator-stimulated phosphoprotein (VASP) assay and electrical impedance aggregometry (74) and by light transmission aggregometry and the VerifyNow P2Y 12 assay (Accumetrics, San Diego, California) (75) .
Phenprocoumon, an oral anticoagulant used in Europe, is a coumarin derivative metabolized by CYP3A4 and CYP2C9. Concomitant treatment with clopidogrel attenuated the antiplatelet effect of clopidogrel and increased the number of nonresponders (76) .
Cangrelor, an ATP analogue, is a parenteral reversible P2Y 12 receptor inhibitor with a short half-life that results in normalization of platelet aggregation approximately 30 min after discontinuation of the infusion. When clopidogrel was given simultaneously with cangrelor and cangrelor was continued for 2 h, there was no inhibition of the P2Y 12 receptor by clopidogrel after the infusion was stopped because the clopidogrel active metabolite was unavailable for binding due to its short half-life (77) . When clopidogrel was started at the time the cangrelor infusion was discontinued, there was inhibition of the P2Y 12 receptor. Importantly, it takes 2 to 4 h for clopidogrel to reach maximal effect. Therefore, there could be an important gap in platelet inhibition while the patient transitions from cangrelor to clopidogrel. CYP inducers. We initially demonstrated that clopidogrel responsiveness could be increased by coadministration with rifampin, a CYP3A4 and CYP2C19 inducer, and that nonresponders could become responsive (5,11). Judge et al. (78) have recently proven that this response is due to increased production of the clopidogrel active metabolite and increased P2Y 12 receptor blockade.
By inhibiting the platelet P2Y 12 receptor, clopidogrel increases intracellular cyclic adenosine monophosphate (cAMP), a key signaling molecule in inhibiting platelet aggregation. Caffeine also increases cAMP levels and has been shown to enhance platelet inhibition by clopidogrel (79) . Other methylxanthines (theophylline) and phosphodiesterase inhibitors (cilostazol) also increase platelet cAMP levels (80) .
Smoking is a known CYP1A2 inducer, and several studies have demonstrated increased platelet inhibition (81), fewer ischemic events (82, 83) , and increased bleeding risk (83) in smokers following clopidogrel administration.
Omega-3 polyunsaturated fatty acids (PUFA) were shown in 1 small prospective randomized trial to increase clopidogrel responsiveness, but the mechanism is unclear (84) .
St. John's wort (Hypericum perforatum) is an herbal product used to treat depression. It also induces CYP3A4 activity. In healthy volunteers who were nonresponders to clopidogrel, St. John's wort 300 mg thrice daily for 14 days improved the platelet inhibitory activity of clopidogrel by increasing CYP3A4 metabolic activity (85) .
Confounding Variables in the Drug Interaction Debate
There are many confounding variables that have contributed to the discordant results regarding potential clopidogreldrug interactions:
1. Dose effect. Inhibition of clopidogrel activation by atorvastatin appears to be dose-dependent (5), consistent with the hypothesis that atorvastatin is a competitive inhibitor of CYP3A4. Studies with high loading doses of clopidogrel (600 mg) and lower doses of atorvastatin (10 to 20 mg) could miss the inhibitory effect of high-dose atorvastatin on a lower clopidogrel loading dose (17). 2. Time effect. Suboptimal production of active metabolite following clopidogrel loading dose administration could eventually be overcome as active metabolite production eventually accumulates from maintenance dosing and binds to initially unblocked platelet receptors. Moreover, only 10% to 15% of the platelet pool is regenerated daily and platelet reactivity decreases with time after the initiating event, making it unlikely that a sustained inhibition of platelet aggregation could be maintained by a drug interaction. Additionally, 3 recent reports suggest that the interaction between CYP2C19 polymorphisms and the effect of clopidogrel on clinical events is limited to a few weeks (86 -88 
Research Challenges in the Drug Interaction Debate
There are many research challenges in scientifically measuring the clinical importance of drug-drug interactions.
1. Study design. Treatment in observational studies is based on clinical need or physician preference, creating selection bias, so these studies can only suggest association, not conclude causality. Claims-based studies are particularly limited by missing or misclassified data. Outcome events in randomized trials are often adjudicated, but multivariable or propensity score analyses in post hoc studies cannot completely adjust for differences in unknown or unmeasured confounders. Only a randomized clinical trial could confirm the importance of a drugdrug interaction at the population level, although the generalizability of the results would be modified by inclusion and exclusion criteria and the potential cost of such a trial would probably be prohibitive. 2. Sample size. The published studies have not been appropriately powered to address clopidogrel-drug interactions. The absolute reduction in major adverse cardiac events at 30 days when clopidogrel is added to aspirin compared with aspirin monotherapy is only 1% (90), making it possible that studies demonstrating no clopidogrel-drug interactions were insufficiently powered to detect a small, but clinically meaningful, difference in event rates when millions of patients are prescribed these drugs. 3. Composite primary end point. Increased individual events related to attenuation of platelet inhibition by a drugdrug interaction (MI, transient ischemic attack) might be neutralized by other events not mediated by platelet aggregation (noncardiac death, target vessel revascularization), producing a net effect that obscures a potential drug interaction. 4. Clinical risk. Only specific patient subgroups may have clinical risk. Low CYP 3A4 metabolic activity, CYP2C19 polymorphisms, age, sex, diabetes mellitus, increased body mass index, and renal insufficiency also decrease clopidogrel responsiveness. Drug-drug interactions in subgroups of patients may not be recognized in population analyses. Moreover, the small reduction in platelet aggregation (10% to 15%) with clopidogrel-drug interactions may not be clinically significant in many subgroups. 5. Patient compliance. A major obstacle to finding a clinical clopidogrel-drug interaction is assuring patient compliance with coadministration of both medications during the study period. Measuring medication use at 1 point in time does not assure continued use of both medications.
Conclusions
There are many pharmacodynamic clopidogrel-drug interactions, but there is no consistent evidence that these interactions have clinical significance. Because the benefit of dual antiplatelet therapy is well established and the existing clinical data on clopidogrel-drug interactions are inconclusive, clinicians should concentrate on initiating proper statin therapy in patients with coronary artery disease and prescribing PPIs for patients at increased risk for gastroduodenal bleeding. The therapeutic benefit of coadministering these medications to appropriate patients should greatly exceed any theoretical harm from clopidogrel-drug interactions that appear to be dose-dependent, time-dependent, and mild compared with the larger challenges of patient compliance and interindividual variability in clopidogrel responsiveness. Clinicians concerned about these interactions have the option of prescribing a different platelet P2Y 12 receptor inhibitor without known drug interactions (39, 72, 91) . Another option is to prescribe a hydrophilic statin in place of atorvastatin; or pantoprazole or ranitidine, an H 2 RA not metabolized by CYP isoenzymes, in place of omeprazole (92) .
